Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00970489 · ClinicalTrials.gov registry record · Phase 3
Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation
A Phase 3 study of Atrial Fibrillation, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,516
- Enrollment target
- 1
- Study location
NCT00970489 is a Phase 3 study of Atrial Fibrillation that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 1,516 participants, below the 2,989-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (49% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00970489, a Phase 3 study of Atrial Fibrillation, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,516 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a large multi-center study to examine whether peri-operative intake of n-3 polyunsaturated fatty acids (PUFA) will reduce the occurrence of post-operative atrial fibrillation or flutter (AF) in patients undergoing cardiac surgery (CS).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Omega -3 fatty acids
Study Locations (1)
Massachusetts
- US, Italy and Argentina - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,516 participants |
| Start Date | 2010-08 |
| Est. Completion | 2012-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00970489
The ClinicalTrials.gov registry entry for NCT00970489 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,516 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,989-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (49% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00970489 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00970489 about?
NCT00970489 is a clinical study titled "Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation". This is a large multi-center study to examine whether peri-operative intake of n-3 polyunsaturated fatty acids (PUFA) will reduce the occurrence of post-operative atrial fibrillation or flutter (AF) in patients undergoing cardiac surgery (CS).
What is the current status of trial NCT00970489?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,516 participants. The study started on 2010-08. Estimated completion is 2012-06.
What conditions does trial NCT00970489 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
What interventions are being tested in trial NCT00970489?
The interventions under investigation include: Placebo (DRUG), Omega -3 fatty acids (DRUG).
Who is sponsoring clinical trial NCT00970489?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00970489 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
RECRUITING · Phase 3
-
Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
RECRUITING · Phase 3
-
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
RECRUITING · Phase 3
-
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
RECRUITING · Phase 3
-
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
RECRUITING · Phase 3
-
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.